Profile data is unavailable for this security.
About the company
Creo Medical Group plc is a medical device company. The Company is focused on the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. It is engaged in research, development and distribution of electrosurgical medical devices relating to the field of surgical endoscopy. The Company has developed the CROMA powered by Kamaptive full-spectrum adaptive technology, which provides optimized surgical capability and patient outcomes. The Kamaptive is a seamless, intuitive integration of multi-modal energy sources. Its CROMA delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused high frequency microwave (MW) energy for controlled coagulation and ablation via a single accessory port. This technology, combined with its range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions.
- Revenue in GBP (TTM)30.80m
- Net income in GBP-21.70m
- Incorporated2016
- Employees287.00
- LocationCreo Medical Group PLCUnit 2 Beaufort Park,, Beaufort Park WayCHEPSTOW NP16 5UHUnited KingdomGBR
- Phone+44 129 160 6005
- Websitehttps://creomedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANGLE plc | 2.19m | -20.13m | 35.49m | 150.00 | -- | 1.25 | -- | 16.24 | -0.0772 | -0.0772 | 0.0084 | 0.0879 | 0.0539 | 0.3521 | 1.21 | 14,573.33 | -49.68 | -- | -56.03 | -- | 69.90 | -- | -920.95 | -- | 4.95 | -- | 0.1656 | -- | 109.99 | -- | 7.17 | -- | -- | -- |
| Tissue Regenix Group PLC | 23.94m | -828.82k | 43.32m | 76.00 | -- | 1.92 | 1,514.21 | 1.81 | -0.0118 | -0.0118 | 0.3393 | 0.3167 | 0.7061 | 1.33 | 6.41 | 314,953.50 | -2.17 | -13.45 | -2.43 | -14.78 | 49.48 | 45.90 | -3.08 | -28.80 | 1.47 | 0.3716 | 0.263 | -- | 20.50 | 13.75 | 36.44 | -- | 9.78 | -- |
| Inspecs Group PLC | 195.14m | -4.11m | 53.89m | 1.67k | -- | 0.5286 | 6.33 | 0.2761 | -0.0404 | -0.0404 | 1.92 | 1.00 | 0.8667 | 2.31 | 7.65 | 116,640.80 | -1.82 | -1.48 | -2.62 | -2.15 | 51.46 | 48.50 | -2.10 | -1.97 | 0.8696 | 0.6441 | 0.377 | -- | 1.16 | 36.45 | 84.22 | -- | 51.04 | -- |
| SDI Group PLC | 65.85m | 4.23m | 61.69m | 503.00 | 14.68 | 1.36 | 7.49 | 0.9368 | 0.0402 | 0.0402 | 0.6256 | 0.4344 | 0.793 | 0.989 | 5.34 | 130,906.60 | 5.12 | 7.85 | 6.11 | 10.01 | 30.84 | 64.06 | 6.46 | 9.48 | 1.35 | 4.85 | 0.321 | 0.00 | -2.56 | 30.46 | 9.30 | 17.22 | 12.08 | -- |
| Creo Medical Group PLC | 30.80m | -21.70m | 113.06m | 287.00 | -- | 1.89 | -- | 3.67 | -0.0709 | -0.0709 | 0.0984 | 0.1655 | 0.4054 | 1.78 | 4.01 | 107,317.10 | -28.56 | -26.07 | -34.84 | -30.94 | 49.68 | 47.58 | -70.45 | -118.24 | 3.01 | -- | 0.1219 | -- | 13.36 | -- | 19.44 | -- | -- | -- |
| EKF Diagnostics Holdings PLC | 50.95m | 4.78m | 131.58m | 309.00 | 27.57 | 1.91 | 13.16 | 2.58 | 0.0105 | 0.0105 | 0.1123 | 0.1516 | 0.6307 | 3.01 | 6.99 | 160,728.70 | 6.34 | 5.20 | 7.35 | 6.13 | 48.05 | 50.04 | 10.05 | 7.91 | 3.08 | 1,703.50 | 0.0175 | 113.68 | -21.05 | 4.34 | 123.28 | -25.30 | 30.37 | -- |
| Tristel Plc | 39.49m | 6.04m | 190.46m | 213.00 | 31.84 | 6.09 | 22.26 | 4.82 | 0.1256 | 0.1256 | 0.8219 | 0.6567 | 0.992 | 1.51 | 6.26 | 185,394.40 | 15.17 | 8.86 | 17.10 | 10.24 | 82.59 | 80.63 | 15.29 | 10.63 | 3.93 | 411.73 | 0.1605 | 109.99 | 15.70 | 10.14 | 351.98 | 6.40 | 9.88 | 18.05 |
| Advanced Medical Solutions Group plc | 131.11m | 11.13m | 533.32m | 1.50k | 48.03 | 2.20 | 23.74 | 4.07 | 0.051 | 0.051 | 0.6011 | 1.12 | 0.3977 | 1.70 | 4.91 | 154,244.70 | 3.38 | 6.54 | 3.64 | 7.06 | 54.45 | 56.75 | 8.49 | 14.82 | 6.80 | -- | 0.2702 | 25.85 | 1.51 | 4.23 | -22.14 | -6.71 | 15.66 | 12.32 |
| Holder | Shares | % Held |
|---|---|---|
| Canaccord Genuity Wealth Ltd.as of 27 Aug 2024 | 36.01m | 9.96% |
| M&G Investment Management Ltd.as of 31 Jan 2024 | 33.53m | 9.27% |
| Baillie Gifford & Co.as of 31 Dec 2023 | 23.42m | 6.47% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2023 | 16.08m | 4.45% |
| Amati Global Investors Ltd.as of 31 May 2024 | 15.71m | 4.34% |
| SVM Asset Management Ltd.as of 31 Dec 2023 | 10.62m | 2.94% |
| Chelverton Asset Management Ltd.as of 31 Dec 2023 | 6.25m | 1.73% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 5.31m | 1.47% |
| Border to Coast Pensions Partnership Ltd.as of 31 Mar 2024 | 4.93m | 1.36% |
| Octopus Investments Ltd.as of 30 Aug 2024 | 3.70m | 1.02% |
